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1. Original protocol, final protocol, summary of changes. 
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A multicenter, prospective, randomized controlled clinical trial based on the 
Swedish angiography and angioplasty registry (SCAAR) platform 
 
 
 
 
 
 
Summary of changes: 
Amendment 1: additional PCI centers, addition of one more thrombus aspiration catheter (Eliminate, 
Terumo). 
Amendment 2: additional PCI centers.  
Amendment 3: additional PCI center. Precision of ECG criterion for posterior MI. 
Amendment 4: (application for permission to include patients unable to give informed consent. This 
was declined by the review board).  
Amendment 5: application for the Data Safety Monitoring Board (DSMB) to perform interim analysis 
due to lower than expected mortality in the overall patient cohort. We were granted permission for 
this.  
Amendment 6: based on the DSMB recommendation, application for permission to increase the 
number of patients in the trial from 5000 to 7200. 
Note to file 1: an additional secondary endpoint was added: “Stroke as reported in the Swedish 
national patient registry”. 
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1. Abbreviations 
CABG  Coronary artery by-pass grafting 
CPI  Coordinating principal investigator 
CRF  Case report form 
IEC  Independent endpoint committee 
PCI  Percutaneous coronary intervention 
PI  Principal investigator 
SCAAR  Swedish Coronary Angiography and Angioplasty Registry 
STEMI  ST-segment elevation myocardial infarction 
SWEDEHEART National Swedish registry on heart disease integrating 
information from four different registries: RIKS-HIA (registry on 
cardiac intensive care units), SEPHIA (secondary prevention 
of heart disease registry), the Swedish heart surgery registry 
and SCAAR 
TAPAS  Thrombus Aspiration during Percutaneous coronary 
  intervention in Acute myocardial infarction Study 
TIMI flow grade Thrombus in Myocardial Infarction flow grade 
UCR  Uppsala Clinical Research Center 
 
 
2. Study rationale  
2.1 Background 
Percutaneous coronary intervention (PCI) is the optimal therapy in ST-segment 
elevation myocardial infarction (STEMI). While this treatment alleviates the major acute 
problem of having an occluded or highly stenosed coronary artery, distal embolization 
of thrombus material often precludes restoration of normal coronary artery flow 1 and 
thrombus material is also thought to play an important role in reperfusion injury.  
 Meta-analyses of randomized trials on adjunctive mechanical devices to 
prevent distal embolization have not demonstrated benefits in mortality, despite 
improvement in myocardial perfusion and reduced distal embolization 2, 3. In fact, some 
mechanical thrombectomy devices may worsen outcome 4. More recently, focus has 
been on aspiration thrombectomy devices. In table 1 an overview of previous trials is 
shown 4-14. 
 In the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) 
detailed information on all patients treated by PCI in Sweden is registered. While 
registry and database information by nature is retrospective, in the present study, for 
the first time, we will use the SCAAR as a prospective platform for conducting a 
randomized clinical multicenter trial. The rationale being that with standardized and 
validated information coupled to other health care registries by social security number 
almost complete follow-up can be assured and that the extra work related to actual 
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study conduction is very limited. Another important advantage by using SCAAR as a 
platform for randomization is the opportunity to include a large number of patients over 
a relatively short time period, thus allowing investigation of hard end points such as 
death, stent thrombosis, restenosis and target vessel revascularization.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 Purpose of the study 
In a multicenter, prospective, randomized controlled clinical trial based on the SCAAR 
platform to compare all cause death, stent thrombosis and TIMI flow grade in patients 
with STEMI treated with PCI and manual thrombus aspiration versus PCI alone.  
2.3 Hypothesis 
In this trial we test the hypothesis that PCI and thrombus aspiration is superior to PCI 
alone in reducing death in patients with STEMI (primary end point).  
Secondary end points are TIMI flow grade, time to re-hospitalization with 
nonfatal reinfarction, heart failure, target vessel revascularization, time to all-cause 
death or new myocardial infarction (first occurring), time to acute coronary occlusion, 
Table 1. Randomized aspiration thrombectomy trial overview
First author Source Trial acronym n Device Follow-up MACE Death Myocardial blush
Haeck, J.D.E. JACC Intv 2009;2:934 PREPARE 284 Proxis, St. Jude Medical 1 month ns ns ns
Sardella, G. JACC 2009;53:309 EXPIRA 175 Export (Medtronic) 9 months ns   P<0.02 P=0.001
Lipiecki, J. Am Heart J 2009;157:583 40 Export (Medtronic) 6 days - - ns
Vlaar, P.J. Lancet 2008;371:1915 TAPAS, 1 year 1071 Export (Medtronic) 12 months ns P=0.02 -
Svilaas, T. N Engl J Med 2008;358:557 TAPAS 1071 Export (Medtronic) 1 month ns ns P<0.001
Ikari, Y. JACC Intv 2008;1:424 VAMPIRE 355 TVAC (Nipro) 8 months P<0.05 ns P<0.001
Kaltoft, A. Circ 2006;114:40 215 Rescue (Boston Scientific) 1 month ns ns -
Silva-Orrego, P. JACC 2006;48:1552 DEAR-MI 148 Pronto (Vascular Solutions) 1 month ns ns P<0.001
Burzotta, F. JACC 2005;46:371 REMEDIA 100 Diver CE (Invatec) 1 month ns ns P=0.020
Lefèvre, T. JACC 2005;46:246 X AMINE ST 201 X-Sizer (eV3) 6 months ns ns ns
Beran, G. Circ. 2002;105:2355 66 X-Sizer (Endicor) 1 month ns ns P=0.03
MACE: cardiac death, nonfatal reinfarction, and target vessel revascularization; ns: not statistically significant. 
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stent thrombosis, restenosis, heart failure, complications of PCI during index 
hospitalization and length of hospital stay.  
2.4 Clinical relevance 
STEMI remains one of the leading causes of death globally. Thrombolysis was a major 
step forward in the treatment of STEMI 15-17 and further progress was done when 
primary PCI was established as a golden therapeutic standard 18. Treatment has been 
further optimized with pre, peri- and post procedure platelet inhibition, statins, 
angiotensin converting enzyme and beta adrenoreceptor blockade. One of the most 
important remaining therapeutic challenges in STEMI is establishment of normal 
coronary flow after PCI because reduced flow is associated with death and heart failure 
19 20. Reduced flow after PCI is closely associated with the paradox that opening of an 
occluded coronary artery is not solely beneficial because of the so-called reperfusion 
injury 21. In reperfusion injury restoration of coronary flow results in arrhythmias, 
contractile dysfunction, microvascular impairment and irreversible myocardial damage 
through apoptosis and necrosis 22. 
 Thrombus aspiration may contribute to improve coronary artery flow post 
PCI 5 9 10 12 14. However, most previous studies on thrombus aspiration have not been 
powered for hard clinical endpoints, such as mortality. To date, the only large-scale 
randomized trial of thrombus aspiration for STEMI to demonstrate a survival benefit is 
the single-center TAPAS trial in which death was a secondary end point 7, 9. Thrombus 
aspiration is easy, quickly performed and a cheap adjunct to PCI. Perhaps because of 
the low-tech nature and the limited possibilities of future patents and economic revenue 
of thrombus aspiration the interest from the medical device industry to initiate new 
large-scale studies in this area is low. However, only large scale randomized studies 
can answer the impeding question of this treatment modality: is thrombus aspiration life 
saving or not?  
Thus, responsibility and initiative for establishing evidence of the clinical 
applicability of thrombus aspiration is left to the scientific community. Thrombus 
aspiration has been adapted by some Swedish centers as routine while others use this 
treatment at the discretion of the operator and others yet again use it scarcely (ref: 
SCAAR). In the recent guidelines from the American College of Cardiology and the 
American Heart Association thrombus aspiration has been upgraded to a class IIa 
recommendation (i.e. it is reasonable to perform the procedure) with a level of evidence: 
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B (i.e. limited populations evaluated) 23. In our view, evidence needs to be established 
before thrombus aspiration becomes routine for some and is discarded by others 
because of the uncertainty related to evidence this far.      
By purpose, the present protocol is planned to be very close in design to 
the TAPAS trial – only with fewer exclusion criteria to investigate the real world 
applicability of TAPAS. 
 
3. Patients and methods 
3.1 Patients 
A total of 5000 patients will be included in the study. 
3.1.1 Patient inclusion 
Individuals for inclusion will be recruited among the patients referred to the participating 
centers for PCI because of STEMI (Figure 1). The patients will not receive any 
honorarium for participation. 
3.1.2 Inclusion criteria 
- Patients with a diagnosis of STEMI as defined by chest pain suggestive 
for myocardial ischemia for at least 30 minutes before hospital admission, time from 
onset of symptoms of less than 24 hours, and an ECG with new ST-segment elevation 
in two or more contiguous leads of ≥0.2 mV in leads V2-V3 and/or ≥0.1 mV in other 
leads or a probable new-onset left bundle branch block. 
- Correspondence between ECG findings and culprit artery pathoanatomy 
- A minimum of 50% stenosis in culprit artery by visual estimate 
- Possibility to perform thrombus aspiration 
3.1.3 Exclusion criteria 
- Need for emergency coronary artery bypass grafting 
- Inability to provide informed consent  
- Age below 18 years 
- Previous randomization in the TASTE trial 
3.2 Consort patient flow chart 
Before study start, each of the hospitals entering data in SCAAR has to decide whether 
or not to participate in the trial (for Danish centers data entry will be done in a separate 
database with a graphical design identical to SCAAR). The understanding will be that all 
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PCI operators in the participating hospitals will actively attempt to include all eligible 
patients in the study period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the SCAAR there is a prospective registration of all patients with STEMI. 
In all participating centers, reasons for not including particular patients will be 
documented on an electronic consort patient flow chart. 
3.3 Follow-up 
Patients in the main study will not be followed-up. The primary end point will be 
monitored using national registries and the secondary end points will be monitored 
using national registries and the SCAAR and Swedeheart databases. 
 In a magnetic resonance imaging (MRI) sub-study, 150 patients will be 
followed by MRI at day 4±2. Please refer to details under caption 9 – sub-studies. 
 
Patients with suspected STEMI referred to primary PCI
N = 5000 
STEMI diagnosis confirmed at coronary angiography. Informed consent obtained
Online 1:1 randomization in SCAAR, guidewire advancement, i.c. nitroglycerin 
Thrombus aspiration and PCI PCI alone
Immediately after PCI: TIMI flow grade
30 days: all-cause death
1, 2, 5 and 10 years: all-cause death and additional secondary endpoints
T A S T E trial flow chart
Figure 1. Flow chart of study design
i.c. : intracoronary; PCI: percutaneous coronary intervention; SCAAR: Swedish Coronary Angiography and Angioplasty 
Registry; STEMI: ST-elevation myocardial infarction.
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3.4 Endpoints 
3.4.1 Primary endpoint 
- The primary endpoint is time to all-cause death at 30 days. These data 
will be obtained from national health registries. 
3.4.2 Secondary endpoints 
- Time to all-cause death after 1year, 2 years, 5 years and 10 years.  
- Time to re-hospitalization with nonfatal reinfarction, heart failure and 
target vessel revascularization after 30 days and 1 year, 2 years, 5 years and 10 years.  
- Time to all-cause death or new myocardial infarction (first occurring) after 
30 days, 1 year, 2 years, 5 years and 10 years.  
- Time to acute coronary occlusion, stent thrombosis and restenosis in 
treated lesions as reported in SCAAR. 
- Reported heart failure and complications of PCI during index 
hospitalization as reported in SWEDEHEART. 
- Length of hospital stay as reported in SWEDEHEART. 
- TIMI-flow grade.  
3.4.4 Endpoint definition 
TIMI-flow grade after PCI is defined as: grade 0 denoted an absence of antegrade flow 
beyond the point of occlusion; grade 1, partial penetration of contrast agent beyond the 
obstruction but incomplete distal filling; grade 2, patency with opacification of the entire 
distal vessel but with delayed filling or washout of contrast agent; and grade 3, normal 
flow 16, 24. Coronary artery bypass surgery after randomization and re-hospitalization 
after index procedure are collected by merging SCAAR with national registries. 
Myocardial infarction is defined as ICD codes I21 and I22, heart failure as I50. New PCI 
are followed in SCAAR. Target lesion revascularization is defined as a new therapeutic 
PCI in the same coronary segment as the index procedure or coronary artery bypass 
surgery after the index procedure. 
3.5 Treatment strategies 
In all patients, initially a guidewire is passed through the culprit lesion. 
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3.5.1 PCI 
For patients randomized to conventional PCI, guidewire advancement is followed by 
balloon dilatation, balloon dilatation and stenting or direct stenting to achieve antegrade 
flow. Post-dilatation of stents is optional. 
3.5.2 Thrombus aspiration and PCI 
For patients randomized to thrombus aspiration, guidewire passing will be followed by 
thrombus aspiration with an Export aspiration catheter (Medtronic Inc., Santa Rosa, 
USA). Continuous manual suction is performed using a proximal-to-distal approach, 
which is defined as active aspiration during initial passage of the lesion. In lesions that 
cannot initially be passed with the thrombus aspiration catheter it is permitted to dilate 
the lesion with an angioplasty balloon up to a maximal nominal diameter size of 2.0 mm 
and attempt to advance the thrombus aspiration catheter for a second time. After 
thrombus aspiration PCI is done as described above. 
3.5.3 Post-procedure platelet inhibition 
After the index PCI, lifelong acetylsalicylic acid in a dose of 75-160 mg per day will be 
prescribed. Duration of glycoprotein 2b/3a inhibitor treatment, clopidogrel or other 
P2Y12 inhibitor is left to the discretion of the treating physician. 
 
4. Statistics and data management 
The data management work and statistical analyses will be performed at Uppsala 
Clinical Research Center (UCR), Uppsala University Hospital, Sweden. 
4.1 Statistical analysis 
Differences between groups in time-to-event endpoints will be assessed with the log-
rank test (for the primary endpoint, patients will be censored at 30 days; analyses at 
other time points will be handled in a similar way). Survival probabilities will be 
displayed and calculated using Kaplan-Meier methodology. Hazard ratios between 
groups will be calculated using Cox proportional hazard model. Differences between 
group means will be assessed with the two-tailed Student's t-test. Chi-square analysis 
or Fisher's exact test will be used to test differences between proportions. A two-tailed 
P-value <0.05 is considered statistically significant. All in accordance with the TAPAS 
study 7.  
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4.2 Safety 
A maximum of 3 months following inclusion of the first 1500 patients and again 
following 3000 patients an independent endpoint committee (IEC) will monitor study 
endpoints. Premature termination of the study will be mandated in the event that one of 
the treatment strategies shows statistically significant inferiority in a degree exceeding 
figures to be expected from previous clinical trials. 
4.3 Analysis population 
The results will be analyzed according to the intention-to-treat principle, i.e. patients 
randomized to a certain group will be followed and assessed irrespectively of the actual 
treatment. Protocol violations will be monitored continuously and the responsible 
centers notified. 
4.4 Sample size calculations 
Sample size is calculated on the basis of two sources. We used cardiac death at 1 year 
in TAPAS which demonstrated a hazard ratio of 1.93 for conventional PCI compared to 
the thrombus aspiration group 7. In addition we used available data from 2005-2007 in 
the SCAAR, which showed an overall one-year mortality of 9.0% in PCI treated STEMI 
patients (approx 6 500 PCI in STEMI/year).  
If the hazard ratio (relative risk) of conventional PCI patient per thrombus-
aspiration and PCI patient is set to 1.3 in this trial, and the 1 year mortality is estimated 
at 9.7% we will need to study 2334 conventional PCI patients and 2334 thrombus-
aspiration + PCI patients to be able to reject the null hypothesis that the experimental 
and control survival curves are identical with a probability (power) of 0.80. The Type I 
error probability associated with testing of this null hypothesis is 0.05 25. In order to 
control for dropouts, crossing from one group to the other, and aspiration device failure, 
5000 patients will be included. 
4.5 Randomization procedure 
Following written informed consent by the patient, the randomization procedure will be 
performed online in the SCAAR database using a 1:1 ratio. There will be a stratified 
randomization according to centre.  
4.6 Case Report Form  
An electronic case report form (CRF) will be generated automatically based on the 
ordinary SCAAR/SWEDEHEART registration form and stored at UCR for each patient 
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included. The patient’s identity will always be confidential. All information in the CRF will 
be in English. The investigators are responsible for ensuring the accuracy, 
completeness, legibility and timeliness of the data recorded in the CRFs. 
 
5. Monitoring  
The study will be monitored using the ordinary SCAAR monitoring system by 
independent professionals. During the study period, monitors will have regular contact 
with the participating departments to ensure that the trial is conducted in compliance 
with the protocol and applicable regulatory requirements. The monitors will ensure that 
the used products are all right and will review source documents for verification of 
consistency with the data recorded in the CRFs. The monitors will also provide 
information and support to the investigator(s).  
Investigators and other responsible personnel must be available during the 
monitoring visits, audits and inspections and should devote sufficient time to these 
processes. Because the data recorded in the CRFs are recognized as source data 
there will be no need for consistency control. 
 
6. Administration 
6.1 Organization 
Swedish, Danish and Icelandic PCI centers with experience and interest in thrombus 
aspiration and willingness to randomize all eligible STEMI patients during the study 
period can participate in the study. 
There will be a country coordinating principal investigator (CPI) for each 
participating country and a principal investigator (PI) for each centre. The CPIs will be 
responsible for the study in the respective countries. Further, they will be key members 
of the steering committee * of the study, and in charge of the study. The PIs will take 
care of the study at centre level. 
6.2 Economy 
The TASTE trial is an academic study, conceived and conducted by cardiovascular 
interventionalists in the respective countries. The study is independent of commercial 
interests. Study logistics, handling of data and statistical assessments will be financed 
by the UCR and the Department of Cardiology, Örebro University Hospital, Sweden. 
The steering committee will apply for grants from public funds and from manufacturers 
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of thrombus aspiration catheters used in the study. Possible external sponsors will have 
no influence on the conduct of the study. 
 
* Members of the steering committee are Stefan James (chairman), Ole Fröbert (CPI, entire study and 
Sweden), Bo Lagerqvist (vice CPI, entire study and Sweden), Leif Thuesen (CPI, Denmark), Torarinn 
Gudnasson (CPI, Iceland) and Göran Olivecrona (substudy organizer) 
 
7. Ethical considerations 
The study will be conducted in accordance with the protocol, applicable regulatory 
requirements and the ethical principles of the Declaration of Helsinki as adopted by the 
18th World Medical Assembly in Helsinki, Finland, in 1964 and subsequent versions. 
The study will be initiated, when the Medical Ethical Committee of Uppsala, Sweden 
has approved the protocol. In the study, we compare two well-known treatments; PCI 
alone with thrombus aspiration followed by PCI. Both treatment regimens are used 
routinely and interchangeable globally and this, in our view, eliminates severe ethical 
considerations in conducting the study. One ethical aspect is that the STEMI patient 
has to be asked for study participation after diagnostic coronary angiography in the 
catheterization laboratory. This will of course be demanding for the patient in an already 
stressful situation. However, this study design is well tested and has been implemented 
in ongoing 26 and previous studies 27 in Scandinavia.  
7.1 Risks, side-effects, advantages and disadvantages in participation 
Patients randomized to PCI alone will be treated according to standard clinical praxis. 
We expect that patients in the thrombus aspiration and PCI arm of the study will benefit 
from less no-reflow phenomena, less heart failure and reduced risk of death although 
this cannot be guaranteed. Previous reports of mechanical thrombectomy devices 
which may worsen outcome 4 are judged to be irrelevant for the present study using 
different technology where such reports have not been published. If manual thrombus 
aspiration and PCI is not statistically superior compared with PCI alone (the study 
hypothesis) we estimate that this adjunctive treatment will be neutral on outcome.    
7.2 Biological material 
Biological material will not be collected or stored in the study [to be determined]. 
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7.3 Guidelines for obtaining informed consent  
Patients will enter the study after signing the informed consent form. Candidate 
participants will receive written information of the study, and they will receive oral 
information by medical doctors participating in the study. The information will be given in 
the catheterization laboratory following diagnostic coronary angiography.  
7.4 Withdrawal 
A patient can be withdrawn from the study at any time, if it is the wish of the patient, or if 
it is medically indicated, as judged by the investigator. A patient’s participation in the 
study will be discontinued, if any of the following criteria applies: a) the patient’s general 
condition contraindicates continuing the study, b) non-eligible patient, c) protocol 
violation. 
 
8. Publication 
Results, positive as well as negative, will be published in an international cardiovascular 
journal. Publication and author issues will be decided by the steering committee on 
basis of general involvement in the study (drafting of protocol, core laboratory. function, 
endpoint committee membership, etc.) and on number of included patients. The 
sequence of additional authors will be determined by the inclusion rates of the 
participating centers.  
 
9. Sub-studies 
 
9.1 MRI Follow-up 
An MRI sub-study assessing infarct size and area at risk will be done in selected 
centers. Patients will be asked to participate in an MR imaging study on day 4±2 
following PCI. MR imaging is performed on a 1.5 T Philips Intera CV system (Philips, 
Best, the Netherlands) with a cardiac synergy coil. The examination is performed with 
subjects in the supine position. After defining the left ventricular (LV) long-axis 
orientation, gradient-recalled echo (GRE) cine images are acquired in long- and short-
axis planes of the LV to enable evaluation of LV function. After intravenous 
administration of a gadolinium-based contrast agent, segmented inversion-recovery (IR) 
GRE images are acquired in the corresponding planes of the LV, enabling detailed 
characterization of the area of infarction. The cine GRE and the IR GRE acquisition are 
undertaken during breath hold. In addition, a GRE velocity-mapping sequence is used 
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to acquire flow-sensitive images perpendicular to the ascending aorta. From these 
images the LV stroke volume and consequently the cardiac output can be determined 
with high accuracy and precision. All image acquisition is triggered by ECG. T2 
weighted cardiac MRI will be performed to determine area at risk according to published 
procedures 28 29, 30.  
Initiation of additional sub-studies are encouraged, but should be accepted 
by the steering committee. No sub-studies are part of the primary application for ethical 
approval of the TASTE study. 
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1. Introduction 
The purpose of this statistical analysis plan is to elaborate on the pre-defined 
statistical analysis in the TASTE trial, and other analyses that were decided before 
clean file. All analyses are performed in accordance with the protocol. Some changes 
and elaborations on the analyses were made in Amendment 5 and 6, but no changes 
are introduced in the SAP. However, this SAP clarifies the secondary outcome 
definitions and analysis populations and introduces a few supplementary analyses. 
The secondary outcome acute coronary occlusion is removed, since it is no longer 
considered to add clinically interesting information to the analysis of stent 
thrombosis. The pre-defined analyses of 1 to 10 years follow-up are not included in 
the primary report and may not be fully covered in this SAP. Text in UPPERCASE 
ARIAL denotes variable names. 
2. Study Objectives  
2.1.  Primary Objective 
The primary objective is to test the hypothesis that PCI and thrombus aspiration is 
superior to PCI alone in reducing death in patients with STEMI. 
2.2. Secondary Objectives 
Secondary objectives are to compare PCI and thrombus aspiration to PCI alone with 
respect to TIMI flow grade, time to re-hospitalisation with nonfatal reinfarction, 
heart failure, target vessel revascularisation, all-cause death or new myocardial 
infarction, acute coronary occlusion, stent thrombosis and restenosis, complications 
of PCI during index hospitalisation and length of hospital stay, in patients with 
STEMI. 
3. Endpoints and background variables 
3.1. Endpoints 
3.1.1. Primary Endpoint 
The primary endpoint is time to all-cause death at 30 days. After termination of 
enrolment the necessary data for the primary variable will be collected for all 
patients. For Swedish patients, data on death is updated from the population registry 
at monthly scheduled time points, and the final analysis data set for the primary 
report and publication will be based on the mid-june 2013 update (about 80 days 
after the last included index PCI) to ensure sufficient reporting of 30-day mortality. 
For non-Swedish patients, data on deaths, death times, and censoring times, will be 
collected with similar quality. Time will be counted from the date of PCI, taken as 
INTERDAT in SCAAR, which is time 0. Surviving patients will be censored at 30 
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days. Patients that withdrew their consent will be censored at the date consent was 
withdrawn. 
3.1.2. Pre-defined Secondary Endpoints 
3.1.2.1. Time to all-cause death after 1year, 2 years, 5 years and 10 years.  
These will not be reported in the primary report but in later follow-up publications. 
Outcomes at 1, 2, 5 and 10 years will be defined in a corresponding way to 30-day 
outcomes. 
3.1.2.2. Time to re-hospitalization with reinfarction, heart failure and target 
vessel revascularization after 30 days and 1 year, 2 years, 5 
years and 10 years.  
Only 30-day outcomes will be included in the primary report. This item comprises 
the three outcomes described below. All times are counted from date of PCI (time 0, 
defined by INTERDAT) using dates only, even if time points should be available in 
some case. Patients without events will be censored at 30 days. Patients that 
withdrew their consent will be censored at the date consent was withdrawn. Patients 
that died without event will be censored at the day of death. Outcomes at 1, 2, 5 and 
10 years will be defined in a corresponding way and reported in future publications. 
- Time from date of PCI to reinfarction as recorded in the SWEDEHEART 
registry. Reinfarction is defined as presence of a diagnosis with ICD code I21 
or I22 (including subcategories), and time of reinfarction is defined as the 
admittance date. To give easily interpreted results, reinfarctions that might 
have resulted in death will not be removed from the analysis. In future 
publications reinfarctions identified from the Swedish inpatient registry may 
also be analysed. 
- Time from date of PCI to heart failure as recorded in SWEDEHEART. Heart 
failure is defined as presence of a diagnosis in ICD code I50 (including 
subcategories), and time of heart failure is defined as the admittance date. 
- Time from date of PCI to target vessel revascularisation. Will be obtained by 
matching SCAAR records on SSN and treated vessel as defined below, for 
vessels with PROCTYP 2 or 3 (stent), disregarding new records with 
PROCTYP 9 (diagnostic). 
3.1.2.3. Time to all-cause death or new myocardial infarction (first occurring) 
after 30 days, 1 year, 2 years, 5 years and 10 years.  
Only 30-day outcomes will be included in the primary report. The time is counted 
from date of PCI (time 0, defined by INTERDAT) using dates only, even if time 
points should be available in some case, to the first occurrence of all-cause death (the 
primary end point) or reinfarction (secondary end point defined above). Patients 
without events will be censored at 30 days. Patients that withdrew their consent will 
be censored at the date consent was withdrawn. Outcomes at 1, 2, 5 and 10 years will 
be defined in a corresponding way and reported in future publications.  
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3.1.2.4. Time to acute coronary occlusion, stent thrombosis and restenosis 
in treated lesions as reported in SCAAR. 
This point comprises three outcomes described below. All times are counted from 
date of PCI (time 0, defined by INTERDAT) using dates only, even if time points 
should be available in some cases. Patients without events will be censored at the 
time of last follow-up. Patients that withdrew their consent will be censored at the 
date consent was withdrawn. Patients that died without event will be censored at the 
day of death. 
- Time from date of PCI to stent thrombosis. Time of stent thrombosis is 
obtained from D_SAT_DATUM, using the first occurrence in any segment.  
- Time from date of PCI to restenosis of treated lesions. Time of restenosis is 
obtained from D_RESTENOS_DATUM, using the first occurrence in any 
segment. 
Acute coronary occlusion will not be analysed, since this subgroup of stent 
thrombosis is not considered to add clinically interesting information.  
3.1.2.5. Reported heart failure and complications of PCI during index 
hospitalization as reported in SWEDEHEART. 
- Heart failure during index hospitalisation will be derived from 
SWEDEHEART as ICD code I50 (including subcategories) as diagnosis for 
the index event.  
- Stroke during index hospitalisation will be derived from SWEDEHEART as 
ICD codes I60-I64 (including subcategories) as diagnosis for the index event.  
- Other complications that will be reported are defined by the following 
SCAAR variables: AVDALLERGISK, AVDBLODMAJOR, 
AVDBLODMINOR, AVDBLODMINI, AVDBEHPSEUDO, 
AVDANNANVASK, AVDNEURO, AVDNJURINSUFF, AVDTAMP, 
AVDREPCI, AVDCABG, AVDHJARTINFARKT, AVDANNANALLV, 
AVDDODSFALL, AVDPROCEDURDOD, AVDBLODNING, 
AVDHEMATOM, AVDHBFALL, AVDFORLANGDKOMPTID, 
AVDVARDTID, AVDULTRALJUD, AVDBLODTRANSFUSION, 
AVDKIRURGISKATGARD, AVDANNANBEHUTOVERKOMP, 
AVDFORTIDAUTSATTNING, LABALLERGILATT, 
LABALLERGIALLV, LABBEHARYTMI, LABHEMO, LABBESTSIDO, 
LABAKUTCABG, LABANNANALLV, LABNEURO, LABVASK, 
LABTAPPAT, LABPERF, LABTAMP, LABPROCEDURDOD. 
3.1.2.6. Length of hospital stay as reported in SWEDEHEART. 
Length of hospital stay for the index event will be computed as 
DISCHARGE_DATE-ADMISSION_DATE+1 using SWEDEHEART data for the 
index event.  
3.1.2.7. TIMI-flow grade. 
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TIMI flow grade after PCI is collected as the TASTE variable 
TASTETIMIFLOWAFTER in SCAAR.  
3.1.2.8. Stroke as reported in the Swedish national patient registry 
This outcome was introduced in a note to file dated November 2011. The outcome 
will not be included in the primary report, since data from the patient registry will 
not be available. Time of stroke will be counted from date of PCI (time 0, defined by 
INTERDAT) using dates only, even if time points should be available in some case, 
to the first occurrence of stroke, defined as ICD code I60-I64 (including 
subcategories). Patients without events will be censored at 30 days. Patients that died 
will be censored at the day of death. Patients that withdrew their consent will be 
censored at the date consent was withdrawn.  
3.1.3. Other secondary end points 
3.1.3.1. Time to all-cause death during the entire follow-up time  
This is the same as the primary variable, but patients are censored at the day of the 
last update from the population registry. For Danish and Icelandic patients, the 
censoring date will be the date when data was sent to UCR.  
3.1.3.2. Left ventricular function during index hospitalisation  
Obtained in the categories <30%, 30-39%, 40-49% and ≥50% from 
D_LEFT_VENTRICULAR_FUNCTION in SWEDEHEART. 
3.2. Treatment administration variables 
3.2.1. Actual treatment 
Obtained from the SCAAR variable ADJTROMB. 
3.2.2. Thrombus aspiration device 
Obtained from TASTEDEVICE. 
3.2.3. Number of treated coronary segments 
Obtained from D_SEGMENTANT. 
3.2.4. Number of treated vessels 
Obtained from SEGMENT. 
3.2.5. Stent diameter and stent length 
Obtained from DIAM and STENTLANGD. If more than one stent is used, mean 
diameter and cumulative stentlength will be obtained from all used stents in the 
individual procedures. 
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3.2.6. Post-dilatation 
Obtained from EFTERDILATATION. Will be reported as Yes if Yes for any 
segment in the patient. 
3.2.7. Direct stenting 
Obtained from PROCTYP. Will be reported as Yes if Yes for any segment in the 
patient. 
3.2.8. Drug-eluting stent implantation and bare metal stent implantation 
Obtained from D_DES_PROC and D_STENT_PROC, procedures with 
D_STENT_PROC=Yes and D_DES_PROC=No will be regarded as bare metal 
stent implantation. 
3.2.9. Numbers of used stents  
Obtained from D_STENTANT. 
3.2.10. Drug-eluting balloons 
Obtained from PROCTYP. 
3.2.11. Complete revascularisation 
Obtained from KOMPREV. 
3.2.12. General success 
Obtained from SUCCESS. 
3.3. Demographic and background variables 
3.3.1. Diabetes yes/no 
Obtained from SCAAR variable DIABETES. Diabetes with insulin treatment 
obtained from SCAAR variable DIABETESINSULIN. 
3.3.2. Thrombus burden  
Obtained from TASTE variable EV_TASTEVISIBLETROMB in SCAAR. 
3.3.3. TIMI flow before PCI 
Obtained from the TASTE variable TASTETIMIFLOWBEFORE in SCAAR. 
3.3.4. Time from symptom onset to PCI  
Time points are defined by the variables SYMPTOM_ONSET_DATE and 
SYMPTOM_ONSET_TIME, and STICKDAT and STICKTID, respectively. 
        
        
Study Code: TASTE    Statistical analysis plan 
SAP Version: 1.0     Date: May 6, 2013 
2013-05-06 CONFIDENTIAL – PROPERTY OF UPPSALA CLINICAL RESEARCH CENTER (UCR) 8(15) 
3.3.5. Time from reperfusion ECG to PCI 
Time points are defined by the variables D_REPERF_ECG_DATE and 
D_REPERF_ECG_TIME, and STICKDAT and STICKTID, respectively. If 
D_REPERF_ECG_DATE or D_REPERF_ECG_TIME are missing, 
PREHOSPITAL_ECG_DATE and PREHOSPITAL_ECG_TIME will be used. 
3.3.6. Previous myocardial infarction 
Obtained from TIDINF. 
3.3.7. Previous PCI  
Obtained from TIDPCI. 
3.3.8. Previous CABG 
Obtained from TIDCABG. 
3.3.9. Treated vessel 
Obtained from SEGMENT (RCA, LM, LAD or LCx), or arterial or venous graft 
according to GRAFT. This will be further summarised over treated vessels by 
patient. 
3.3.10. ACC/AHA lesion class 
Obtained from STENOSKLASS. This will be further summarised over treated 
vessels by patient. 
3.3.11. Other background variables  
- Hospital: CENTREID 
- Sex: D_GENDER 
- Killip class: KILLIPKLASS 
- Finding (Inconclusive, Normal/Atheromatosis, 1-, 2- or 3-vessel disease, or 
Main stem stenosis): FYND 
- Age: D_AGE_ANGIOPCI 
- BMI: D_BMI. Note that this variable is missing for a substantial number of 
patients. 
- Smoking status: SMOKING_STATUS. 
- Lipid lowering drugs: HYPERLIP. 
- Hypertension treatment: HYPERTON. 
- Previous myocardial infarction: TIDINF 
- Previous coronary by-pass grafting: TIDCABG 
- Medications prior to procedure: 
o ASA: ASAFORE 
o Clopidogrel/ticlopidin: CLOFORE 
o Ticagrelor: TICFORE 
o Prasugrel: PRAFORE 
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o Warfarin: WARFORE 
If the variables are missing or unknown in SCAAR, corresponding information may 
be obtained from SWEDEHEART records. 
4. Study design 
TASTE is a controlled, randomised, open label trial to investigate the effect of PCI 
with manual thrombus aspiration versus PCI alone, in patients with STEMI. 
Treatment allocation and data collection was performed using the SCAAR platform, 
and the primary outcome of death was obtained from national registries. Patients 
were randomised in a 1:1 ratio using block randomisation stratified on hospital. 
Although the study was not blinded, investigators and steering committee did not 
have access to treatment allocation data or data summaries by treatment during the 
study.  
 
The trial was originally planned to randomise 5000 patients. Due to a lower than 
expected rate of death, the maximum number of patients was increased to 7200 in 
Amendment 6, together with the adoption of a group-sequential plan that would 
allow early termination after about 4800 patients. The study design changes and 
sample size update were decided by study team members with access to data on 
overall mortality rate, but without access to any data that allowed treatment 
comparisons. 
 
The trial was monitored by an independent data safety monitoring board (DSMB) 
that received unblinded summaries of data at two interim analyses, originally 
planned at 1500 and 3000 patients. The mandates for the DSMB were clarified in 
Amendment 5 prior to the first interim analysis, to only evaluate specific safety 
concerns and not differences in efficacy in a single interim analysis after 2500 
patients. The mandates were expanded in Amendment 6, to evaluate efficacy in a 
second interim analysis including at least 4800 patients, with the option to either 
declare statistical significance, recommend early termination of the study because of 
a low probability to obtain a statistically significant result at the end of the study, or 
to recommend that the study is continued until 7200 patients have been enrolled.  
5. Interim analysis plan 
The interim analysis for efficacy was performed after 30 days follow-up on all-cause 
death has been obtained for 4798 patients, which was deemed sufficiently close to 
the 4800 specified in the interim analysis plan. The DSMB was entrusted to either 
declare that a statistically significant treatment difference has been detected for the 
primary variable and that enrolment will stop, recommend that the study is 
terminated due to a low confidence in the possibility to detect a meaningful treatment 
difference after 7200 patients have been included (futility), or recommend that the 
study continues until 7200 patients have been included. The recommendation of the 
DSMB (2012-08-29) was to continue the study.  
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Statistical significance at the interim analysis was defined by p<0.01 (two-sided). If 
significance is not obtained, the DSMB had the opportunity to recommend stopping 
the study due to a low confidence in the possibility to detect a meaningful treatment 
difference. The recommended, non-binding, criterion for futility stopping was that 
the interim analysis gives p>0.49, based on a spending of beta=0.05. To aid the 
decision, the conditional probability of obtaining a significant result at 7200 patients, 
and the estimated hazard ratio with 95% confidence interval, was calculated.  
 
If the study was not discontinued after the interim analysis, statistical significance at 
the final analysis, even if the goal of 7200 patients was not reached, is defined by 
p<0.0471 (two-sided), to ensure that the total type I error rate is below 5%. The p-
value boundaries were calculated based on interpolated alpha- and beta-spending 
methodology, using East version 5.4.2.0 (Cytel, Inc., Cambridge, MA, USA), for a 
comparison of the proportion patients that die within 30 days. By estimating the 
expected accumulated information fraction by the number of patients, these 
boundaries are valid for the primary analysis, time to death within 30 days. In the 
event that more than 7300 patients are included in the final analysis, the p-value for 
declaring statistical significance was to be recalculated using Haybittle-Peto alpha-
spending, based on 4800 patients in the interim analysis and the actual number of 
patients in the final analysis, with expected information fractions estimated using the 
number of patients. Since the study was continued and the final number of patients is 
below 7300, statistical significance for the primary variable will be defined by a two-
sided p<0.0471. 
 
6. Definition of Analysis Populations 
All analyses will be performed on the full analysis set (FAS), comprising all 
randomised patients with the following exceptions: 
- Patients where the date of index PCI (INTERDAT) is unknown. These 
patients lack a SWEDEHEART record relating to the index event. For two 
patients, patient number 110022 and 129065, a matching SWEDEHEART 
record could be found although the initial record matching the randomisation 
had been removed, leaving 14 patients without date of index PCI. 
- Patients that did not give initial informed consent or withdrew consent within 
a short time span. In total, four patients (118068, 118001, 128016, and 
133150)  are excluded from the FAS for this reason.  
The analysis population was determined at a meeting 2013-03-26 using a document 
prepared by Bo Lagerqvist. Some changes may occur up to the formal clean file 
meeting, and the patients excluded from the FAS will be described in the data base 
closure document. 
 
The eligible patient set (EPS) consists of all patients in Sweden with STEMI referred 
to PCI during the enrolment period, according to SWEDEHEART. The EPS will be 
used to compare background variables and primary outcome in the selected TASTE 
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population to the non-included population, as an aid to assess the external validity of 
the randomised comparison. 
7. Description of statistical analyses 
7.1. Study conduct and Subject/Patient disposition 
Patients that withdrew their informed consent are described in the data base closure 
document. The number of patients that are excluded from the FAS due to missing 
index date and due to missing informed consent will be described by randomised 
treatment. FAS patients missing or having no in either 
EV_TASTEPATIENTSUITABLE or EV_TASTECONCENT, and patients without 
a PCI, will be tabulated by randomised treatment. The patient numbers will be taken 
from the data base closure document.  
7.2. Baseline Characteristics and Treatment Group 
Comparability 
Background characteristics will be tabulated using descriptive statistics such as 
absolute and relative frequencies, mean and standard deviation, and quartiles, as 
appropriate. 
7.3. Treatment Administration/Compliance 
Actual treatment and data for the index PCI will be described using descriptive 
statistics such as absolute and relative frequencies. 
7.4. Efficacy analyses 
7.4.1. General considerations 
All efficacy analyses will be performed as described in the protocol, Amendment 6, 
using the FAS, for observed cases only. 
 
Differences between groups in time-to-event endpoints will be assessed with the log-
rank test. For the primary endpoint, patients will be censored at 30 days (where the 
day of PCI is day 0); analyses at other time points will be handled in a similar way. 
Survival probabilities will be displayed and calculated using Kaplan-Meier 
methodology. Hazard ratios between groups will be calculated using Cox 
proportional hazard model. Differences between group means will be assessed with 
the two-tailed Student's t-test. Chi-square analysis or Fisher's exact test will be used 
to test differences between proportions. Estimates will be presented with nominal 
95% confidence limits and nominal 2-tailed p-values. 
7.4.2. Primary efficacy analysis 
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Time to death within 30 days, and within the study up to 30 days after the inclusion 
of the last patient, will be presented by randomised treatment using Kaplan-Meier 
curves.  
 
The treatment hazard ratio of death within 30 days, from a Cox proportional hazards 
model with treatment as the only factor, will be presented with its nominal 95% 
confidence interval and the nominal p-value from the log-rank test. Surviving 
patients will be censored on day 30, where the day of PCI is day 0. Statistical 
significance will be determined by p<0.0471 as by the interim analysis plan.  
 
As a supplementary analysis, the proportion patients that died before or on day 30 
after PCI will be tabulated and analysed using logistic regression with randomized 
treatment as a factor, and the odds ratio presented with its 95% confidence interval 
and p-value from the Pearson chi-square test.  
 
To assess possible impact of the design changes on the interpretation of the results, a 
comparison of treatment hazard ratios based on the primary variable will be 
presented, comparing patients enrolled up to the date that the interim analysis data 
was extracted from the registry, to patients enrolled after that date. This analysis will 
be based on a Cox model with factors randomized treatment, study period, and 
interaction. A sensitivity analysis using a Cox model with factors randomized 
treatment and center will be performed. 
7.5. Secondary efficacy analyses 
7.5.1. Time to re-hospitalization with reinfarction, heart failure, target vessel 
revascularization, composite of all-cause death and re-hospitalisation 
with reinfarction, stent thrombosis, restenosis in treated lesions, and 
stroke, within 30 days 
These variables will be described and analysed in the same manner as the primary 
variable, including a supplemental analysis of proportions. No sensitivity analyses 
will be performed.  
7.5.2. Reported heart failure and complications of PCI during index 
hospitalisation 
The outcomes will be presented as number and frequency of patients with each 
complication, the related estimated odds ratio with 95% confidence interval from a 
logistic regression model with factor randomised treatment, and the p-value from a 
Pearson's chi-2 test. Due to the multiplicity of tests, the p-values for complications 
should be interpreted as a descriptive signalling device. 
7.5.3. Length of hospital stay 
Length of hospital stay will be presented using descriptive statistics, the Hodges-
Lehmann estimate of distribution shift between the treatments with 95% confidence 
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interval, and the p-value from a Wilcoxon's rank sum test. An additional confidence 
interval for the difference in means may be computed using bootstrap. 
7.5.4. TIMI flow 
TIMI flow will be tabulated by randomised treatment and in a shift table by 
randomised treatment and TIMI flow before PCI. The p-value from a Pearson's chi-
2-test will be presented. A supplementary exact Wilcoxon's rank sum test will be 
performed as a test for trend. 
7.5.5. Left ventricular function 
Left ventricular function will be tabulated by randomised treatment. The p-value 
from a Pearson's chi-2-test will be presented. A supplementary exact Wilcoxon's rank 
sum test will be performed. 
7.6. Imputation of Missing Data 
No imputation of missing data will be performed. For the primary variable, death 
time within 30 days, follow-up is complete for the patients in the FAS, and the 
number of randomised patients not included in the FAS is considered too small to 
substantially alter any conclusions.  
7.7. Subgroup and interaction analyses 
Subgroup analyses will be performed for the primary variable using Cox regression 
with factors randomized treatment, subgroup, and randomized treatment-subgroup 
interaction. The results will be presented as the hazard ratio with 95% confidence 
interval for each subgroup and the p-value for interaction. Data will be presented 
descriptively as Kaplan-Meier curves for each treatment in each subgroup. The 
following subgroups will be analysed: 
- Sex, male/female. 
- Age, ≤65/>65 years. 
- Smoking, current smoker/not current smoker. 
- Previous myocardial infarction, yes/no. 
- Diabetes, yes/no. 
- Thrombus burden, 0/1/2/3/4/5 and 0-3/4-5.  
- TIMI flow grade, 0/1/2/3 and 0-1/2-3. 
- Time from symptom onset to PCI, below median/above median, and below 2 
hours/above 2 hours. 
- Time from first ECG to PCI, below median/above median. 
- Treated vessel, LM/LAD/LCx/RCA/Graft and LM+LAD+LCx/RCA. 
- Proximal culprit lesion, segment 1,2,5,6,7,11/others. 
8. Determination of sample size 
The original sample size calculation was based on one-year mortality, and the study 
was planned to include 5000 patients to be able to detect a  hazard ratio of at least 
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1.3, based on time to death within one year, at the 5% confidence level with 80% 
power. This calculation was updated in a protocol amendment to reflect the pre-
defined primary outcome, which is time to death within 30 days. In addition, the 
updated sample size calculation accounts for a lower overall mortality rate than 
expected as revealed by a blinded interim analysis, and the introduction of a formal 
interim analysis with possible stopping for efficacy. 
 
A blinded interim analysis was performed to estimate the overall all-cause death 
proportion at 30 days after randomization. With blinded is meant that an overall 
estimate of the all-cause mortality rate for the total group of patients in the study was 
determined while keeping the treatment group allocation blinded, and no statistics by 
randomized treatment group was calculated. Actions were taken to ensure personnel 
involved in the sample size calculation and calculation of the overall mortality rate 
had no access to treatment group allocation.  
 
The blinded interim analysis, as per January 15, 2012, resulted in an overall rate of 
2.9% (the Kaplan-Meier estimate). The all-cause mortality proportion at 30 days was 
estimated to 3.5% for patients randomized to conventional PCI by assuming a 
difference at 30 days between patients randomized to conventional PCI and 
thrombus-aspiration + PC corresponding to an odds ratio of 1.5 (based on previous 
study TAPAS). 
 
Assuming a 3.5% 30-day mortality rate for conventional PCI, odds ratio at least 1.5 
(conventional PCI/ thrombus-aspiration + PCI), overall type I error 0.05, and an 
interim analysis at 67% of the total sample size, with interim stopping for 
significance with p<0.01, and interim stopping for futility with p>0.493 (non-
binding), a total of 7138 patients would give 80% power of obtaining a significant 
result at the 5% level using 2-sided tests for the odds ratio of death within 30 days. 
The power for the log-rank test of time to death within 30 days is assumed to be 
similar. 7138 is rounded upwards to 7200 patients. The calculations were done using 
interpolated alpha- and beta-spending methodology using East version 5.4.2.0 (Cytel, 
Inc., Cambridge, MA, USA). 
9. Changes in the Planned Analysis 
No changes were made from the amended protocol in the analysis of the pre-
specified outcomes. Changes introduced in the amendments did not affect the 
statistical methods employed for hypothesis testing. Compared to the initial protocol, 
the amendments clarified that for the primary analysis, time to death was to be 
censored at 30 days, and introduced a group-sequential analysis plan. Methods for 
calculating point estimates and confidence intervals, consistent with the hypothesis 
tests, have been added in Amendment 6 and the SAP. This SAP clarifies secondary 
outcome definitions and analysis populations and introduces a few supplementary 
analyses. The secondary outcome acute coronary occlusion is removed, since it is no 
longer considered to add clinically interesting information to the analysis of stent 
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thrombosis. Left ventricular function is added as a secondary outcome, and a number 
of subgroup analyses are introduced. 
10. Description of Derived Variables 
See variable descriptions in Section 3. 
11. Description of Output 
Output shells will be described in a separate document. 
12. Statistical software 
Statistical analyses will primarily be performed using SAS v. 9.3 or later. In addition, 
R version 12.15.0 or later or SPSS may be used. 
